TIGIT and Miyoshi myopathy: Recent cellular experiments demonstrate that EZH2 inhibitors augment the antitumor effects of TIGIT monoclonal antibodies by modulating the TIGIT-CD155 axis between NK and MM cells (Liu et al., 2023).